HAIFA, Israel--(BUSINESS WIRE)--Sept. 27, 2005--Pluristem Life Systems, Inc. (OTC BB:PLRS - News), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that the Board of Directors appointed Zami Aberman as Chief Executive Officer. Shai Meretzki will resume his position as Chief Technology Officer.

Zami Aberman has 20 years of Experience in Marketing and Management in the Hi-Tech Industry. He held Chief Executive and Chairman positions in Israel, the USA, Europe, Japan and Korea. He operated within high-tech global companies in the fields of Automatic Optical Inspection, network security, Video over IP, software, chip design and robotic markets. Mr. Aberman served as the chairman of Rose Hitech Ltd., a private investment company; as chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a director of Ori Software Ltd., involved in data management. Before those positions he served as the President and CEO of Elbit Vision Systems), a public company traded on the OTCBB market (EVSNF.OB) which supplies inspection systems for the microelectronic industry. As well, Mr. Aberman served as President and CEO of Netect Ltd specializing in the field of Internet security software, he was the Co-Founder, President and CEO of Associative Computing Ltd, developing an associative parallel processor for real-time video processing, he served as chairman of Display Inspection Systems Inc specializing in laser based inspection machines and he served as President and CEO of Robomatix Technologies Ltd, a public company (RBMXF.OB).

In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.

"We welcome Zami who we are more than confident will transition Pluristem and take it to the next level of clinical trial development, creation of effective strategic alliances and exposure of the Company's vital technology to a new and growing audience. He is a demonstrated business professional and possesses the leadership needed for such transitions. With Shai Meretzki back at the helm in the lab, Yossi Keret keeping investors informed and fully compliant, Zami's proven leadership will be all the more effective," stated Doron Shorrer, Chairman of the Board of Directors.

"It is my sincere hope to translate my many years of building and funding companies in the technology industry and focus those efforts on Pluristem, which, I believe possesses unique and sorely needed technology that could forever change the field of stem cells and save millions of lives," stated Zami Aberman.

About Pluristem

Pluristem is a biopharmaceutical company developing stem cell products for cell regenerative therapy. Pluristem's platform for expanding stem cells offers breakthrough technology and multiple product opportunities in many therapeutic areas. Pluristem has exclusive rights to the Plurix(TM) cell expansion system under a licensing agreement with Technion Institute of Technology and the Weisman Institute of Science.

For more information, visit the Company's website at: www.pluristem.com.

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include statements regarding Mr. Aberman transitioning Pluristem and taking it to the next level of clinical trial development; his creation of effective strategic alliances and exposure of the Company's vital technology to a new and growing audience; that Shai Meretzki will continue to be in charge of our lab; that Yossi Keret will keep our company fully compliant; and that we have technology that could forever change the field of stem cells and save millions of lives. Actual outcomes and our actual results could differ materially from those in such forward-looking statements, as we may find that working capital is used more quickly than anticipated, we may face unanticipated expenses, and we may not be able raise funding when we require it, our technology may not prove successful, our competition may produce better or cheaper products, we may not be able to develop our products sufficiently to obtain regulatory approvals, we may not be able to retain key employees, we may face unexpected difficulties in complying with regulatory requirements, and we may not identify or successfully develop programs that create shareholder value. For further risk factors see the Company's latest 10-KSB filed with the SEC.